19 results about "Gastric Disorders" patented technology

The invention discloses a long-acting pellet suitable for gastric absorption and a preparation method of the long-acting pellet. The long-acting pellet is prepared from the following components in parts by mass: 0.01-1 part of a medicine, 1-2.5 parts of a filler, 0.2-0.7 part of a modified pore-foaming agent mixture, 1-2.5 parts of an improved adhesive mixture and 0.1-0.7 part of an improved sonokinetic response agent. Wherein the modified pore-foaming agent mixture is prepared from a modified pore-foaming agent and glycosylated saponin, the modified pore-foaming agent is prepared by mixing a pore-foaming agent and seleno-amino acid according to a mass ratio of 4: 1, the improved adhesive is mixed with the adhesive through BHP-SH, and ionic crosslinking is performed by using CaCl2 to form a covalent ion dual network, so that the stomach adhesiveness is enhanced; the sonokinetic response agent is improved by the coated poria cocos extract, and the long-acting pellet is prepared by adopting a wet granulation method or a fluidized bed method, has the characteristics of slow release, long acting, targeted stomach absorption and responsive drug release, and is suitable for treating stomach diseases such as gastritis.

This invention discloses a pharmaceutical composition and its preparation method for treating atrophic gastritis, precancerous lesions of the stomach, and stomach cancer, belonging to the field of traditional Chinese medicine preparation technology. The pharmaceutical composition is prepared by a specific two-step microbial fermentation process using Astragalus membranaceus, Hericium erinaceus, Curcuma zedoaria, Actinidia chinensis root, Camptotheca acuminata fruit, Hedyotis diffusa, Coptis chinensis, Taraxacum mongolicum, Viola yedoensis, Corydalis yanhusuo (processed with vinegar), Phellodendron chinense, Solanum nigrum, Scutellaria baicalensis, Panax notoginseng, Zingiber officinale, Piper cubeba, Cuttlebone, Fritillaria thunbergii, roasted soybean, and red yeast rice. This invention significantly improves the bioavailability of the active pharmaceutical ingredients through the synergistic effect of the multifunctional groups of traditional Chinese medicine and the enhanced effect of microbial fermentation. It can systematically reverse gastric mucosal atrophy and intestinal metaplasia, effectively improve microcirculation, and inhibit Helicobacter pylori, while also exhibiting good safety. This provides a novel and effective treatment for the aforementioned gastric diseases.

The invention is suitable for the technical field of medicine, and provides a stomach medicine capsule and a preparation method thereof, the stomach medicine capsule is prepared from 20-30 parts of Chinese angelica, 7-11 parts of phoenix-tail fern, 15-19 parts of radix berberidis, 5-9 parts of radix aucklandiae, 2-4 parts of reed seed, 13-17 parts of sea snail and auxiliary materials; the preparation method comprises the steps of raw material pretreatment, ethanol reflux extraction, vacuum concentration, spray drying, mixing granulation, capsule filling and packaging. The traditional Chinese medicine raw materials in a specific proportion are screened, the synergistic effect of resisting inflammation and bacteria, regulating qi to relieve pain, nourishing blood and repairing, and relieving acid and protecting the stomach is achieved, and the problems that an existing stomach medicine is single in effect and large in side effect are solved; meanwhile, extraction and drying processes are optimized, the dissolution rate of effective components and the stability of the preparation are improved, and the traditional Chinese medicine composition is suitable for treating stomach diseases such as acute and chronic gastritis, gastric ulcer and hyperacidity, high in safety and suitable for long-term administration.

The application discloses a kind of biological hybrid micro machine population oral delivery system of imitating Helicobacter pylori survival mechanism, belong to oral stomach medicine delivery technical field.The system is by active power module (flagellum driven chlamydomonas reinhardtii), environmental regulation module (acid urease modified on algal surface) and multifunctional load module (macrophage membrane wrapped drug-loaded nanoparticles) synergistic assembly through polydopamine (PDA) spatial conformation control layer is formed.Active power module utilizes self-movement ability to penetrate mucus barrier and extend intracavity retention time to 12 hours or more;Environmental regulation module produces local alkalization effect by catalyzing urea hydrolysis, provides chemical shield for system in extremely acid environment of pH 1.0-3.0, protects active power module from gastric acid inactivation;Multifunctional load module is accurately delivered to gastric epithelial cells by inflammation targeting effect, such as CRISPR / Cas9 biological macromolecule, and realizes up to 31.8% in-vivo gene editing efficiency.The application provides a non-invasive, modular active delivery platform for the precise treatment of gastric diseases such as gastritis through the synergistic effect of physical penetration, metabolic reprogramming and gene intervention.

The invention discloses a defoaming agent adaptive to a digestive tract environment, and a preparation method and application thereof, and relates to the technical field of digestive tract examination assistance. The defoaming agent comprises simethicone, hyaluronidase, bromelain and sodium bicarbonate, and the preparation form is a capsule in which a quick-release drug-loading unit and an enteric drug-loading unit are mixed. The preparation method comprises the following steps: preparing the quick-release drug-loading unit, preparing the enteric drug-loading unit, and mixing and encapsulating. The defoaming agent is orally taken 25-35 minutes before gastroscopy, a closed loop of gastric acid neutralization, thick mucus degradation and foam removal effects can be formed, the problem of poor defoaming caused by mucus wrapping foam is solved, the field of view in the stomach is optimized, and the accuracy of stomach disease diagnosis is guaranteed.

This invention discloses a high-load XOR tumor-targeting therapy nanoplatform based on ROS activity and its applications, belonging to the field of nanobiomaterials. This high-load XOR tumor-targeting therapy nanoplatform, using a zeolite imidazole framework-8 (ZIF-8) as a carrier, contains xanthine oxidoreductase (XOR) with cellular enzymatic activity. It possesses the ability to target tumor cells and induce intracellular reactive oxygen species (ROS), leading to tumor cell death. Induction of intracellular ROS in tumor macrophages (TAMs) also supports the differentiation of macrophages into M1 types. ROS-induced apoptosis in tumor cells produces a series of tumor-associated antigens, which further promotes the infiltration and activation of macrophages in the tumor microenvironment. This, in turn, leads to increased infiltration of CD8+ T cells in the tumor, whose cytokine profile shows cytotoxic effects, indicating successful induction of an adaptive anti-tumor response. This novel nanomaterial offers a promising new strategy for the immunotherapy of gastric diseases.

The invention belongs to the technical field of medicines, and particularly relates to application of hibiscus (the hibiscus is a plant hibiscus flower and an extract and an active monomer thereof) in preparation of medicines for treating stomach diseases (atrophic gastritis, gastric mucosal lesion and gastric cancer). The invention discloses application of hibiscus syriacus in treatment of gastric diseases. The application comprises at least one of chronic atrophic gastritis treatment, gastric mucosa protection and gastric cancer prevention. In-vitro experiments show that the shrub althea flower extract, shrub althea flower polyphenol, syringic acid (I), protocatechuic acid (II), kaempferol (III) and kaempferol-7-O-beta-D-glucoside (IV) have obvious antioxidant activity and gastric mucosa protection activity, can obviously reduce the ROS content in ethanol-induced GES-1 cells and the expression of apoptosis marker protein Caspase-3 / Bax, and have a wide application prospect.

The application discloses a short-wave ultraviolet irradiation-based stomach disease treatment instrument, and belongs to the technical field of medical equipment.The application comprises a treatment instrument main body, a main pipe body, a probe end, an ultraviolet emission end and a treatment control module for controlling the treatment instrument main body; the modular design of the treatment instrument main body and the combination with the ultraviolet emission end improve the clinical operability and treatment effect, the combination with the rotary toothed disc driving mechanism enables the ultraviolet emission end to realize all-around twisting, covers the stomach area, the light-transmitting layer blocks infrared radiation while ensuring the ultraviolet transmittance, reduces the thermal stimulation on the stomach tissue, and enables medical staff to observe the irradiation effect in real time, realizes visual treatment, the treatment control module realizes the precision and intelligence of stomach disease treatment through a multi-unit cooperative architecture, generates a personalized scheme based on the disease type and the lesion position, monitors the physiological indexes of patients in real time and dynamically adjusts the treatment parameters, and improves the treatment safety and effectiveness.

The invention provides a stomach invigorating and qi guiding pill, a preparation method and application thereof, and relates to the field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 12 to 15 parts of flos caryophylli, 12 to 15 parts of rhizoma cyperi, 12 to 15 parts of fructus aurantii immaturus, 12 to 15 parts of cortex magnoliae officinalis, 25 to 30 parts of pericarpium trichosanthis, 12 to 15 parts of radix linderae, 6 to 9 parts of rhizoma zingiberis, 12 to 15 parts of cortex cinnamomi, 9 to 12 parts of radix paeoniae alba, 25 to 30 parts of radix astragali seu hedysari, 25 to 30 parts of radix pseudostellariae and 9 to 12 parts of radix bupleuri. The stomach-invigorating and qi-guiding pill is used for treating deficiency-cold in spleen and stomach, deficiency of qi and blood and intermingled phlegm and blood stasis, and has the effects of tonifying spleen with fragrance, relaxing bowels, promoting the circulation of qi, tonifying spleen, replenishing qi and harmonizing stomach, and reducing phlegm with sweet and warm taste. The pill is fixed on the Zhongwan acupoint, the Shenque acupoint, the Tianshu acupoint and the Zusanli acupoint through application, and stomach diseases caused by malignant tumors can be effectively treated.

According to the present invention, strains for preventing gastric cancer have been identified and, in particular, it has been identified that when a microbiome was administered together with H. felis, which is known to cause various gastrointestinal diseases by inducing gastric tissue damage and inflammatory responses, gastric tissue damage and inflammatory responses did not occur. Furthermore, it has been identified that the microbiome suppresses gastric tissue damage when administered even in cases already infected with H. felis. Therefore, the microbiome can be effectively used as a preventive or therapeutic agent for normalizing gastric intestinal metaplasia, which is a precancerous lesion, and for suppressing gastric carcinogenesis.

This invention discloses a gelling material for treating gastric diseases and its preparation method, belonging to the field of pharmaceutical preparation technology. The gelling material is composed of 8-10g of Codonopsis pilosula extract, 6-10g of Bletilla striata extract, 6-8g of Dioscorea opposita extract, 2-4g of Citrus reticulata peel extract, 2-3g of gelatin, 2-4g of xylitol, 0.1-0.2g of citric acid, and 60.8-73.9g of purified water. As a carrier matrix, the gelling material of this invention exhibits good compatibility with commonly used antacids (such as calcium carbonate), PPIs (such as omeprazole), antibiotics (such as amoxicillin and clarithromycin), and traditional Chinese medicine extracts. During preparation, the above-mentioned active pharmaceutical ingredients (APIs) can be uniformly dispersed in the gel matrix, achieving integrated synergistic treatment of "mucosal protection + acid suppression / bactericidal action" without compromising their chemical stability or causing burst release problems, providing an ideal platform for developing compound gastric disease preparations.

It has been identified in the present invention that, in addition to Helicobacter felis, strains causing cell hyperplasia, metaplasia, dysplasia, and the like in gastric tissues. Therefore, a gastric cancer mouse model in which gastric lesions are induced in mice can be provided using a gastric microbial transplantation (GMT) technology, and various gastrointestinal diseases can be diagnosed and the prognosis thereof can be predicted by measuring the concentrations of the strains.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

The invention belongs to the technical field of endoscopes, particularly relates to an intragastric double-endoscope collaborative visual diagnosis device, and aims to solve the problem that due to the fact that part of gastric diseases can be clearly diagnosed only by depending on long-time continuous observation, an existing gastroscope is difficult to meet the dynamic monitoring requirement. The capsule gastroscope comprises a capsule gastroscope body, a flexible gastroscope body and a magnetic attraction mechanism. The capsule gastroscope is internally provided with a liquid storage cavity used for containing adhesive liquid and has an auxiliary observation mode and a continuous observation mode. And the front end part of the flexible gastroscope is detachably connected to the capsule gastroscope. When the intragastric double-endoscope collaborative visual diagnosis device is used, after the flexible gastroscope conveys the capsule gastroscope to an observation position, the magnetic attraction mechanism applies magnetic attraction force to fix the capsule gastroscope to the stomach wall and trigger release of the adhesive liquid, the adhesive liquid adheres and fixes the capsule gastroscope to the stomach wall, the capsule gastroscope independently and continuously collects intragastric images, and the capsule gastroscope is used for detecting the intragastric images. And the capsule gastroscope falls off from the stomach wall until the bonding liquid loses efficacy due to the effect of gastric juice.

Described and disclosed herein are various embodiments of methods, systems, devices and components configured to treat nausea and vomiting with gastric electrical stimulation (GES). Such methods, systems, devices and components may be for temporary or permanent gastric electrical stimulation applications.

The invention relates to the technical field of microorganisms, and particularly discloses a kit and a probiotic product for predicting, diagnosing, preventing and treating the occurrence risk of gastric diseases of a helicobacter pylori (HP) infected person. The method comprises the following steps: (1) screening specific and enriched microorganisms of each stomach disease (chronic gastritis, superficial gastritis, atrophic gastritis, intestinal metaplasia and stomach cancer) in HP infected persons, and preparing the microorganisms into a kit for predicting and diagnosing the risk of disease occurrence; and (2) screening specific or enriched microorganisms in healthy people (HP positive infected people are not likely to develop stomach diseases) infected with HP to prepare probiotic products for preventing and treating stomach diseases. HP-denier is colonized in the stomach and becomes an absolutely dominant microflora in the stomach (the abundance exceeds 50% of the total microflora), but the current antibiotic quadruple therapy enables HP to generate drug resistance. The kit and the probiotic product provided by the invention can predict, diagnose, prevent and treat stomach diseases on the premise of avoiding generation of HP or enhancing drug resistance.

The present invention discloses a gastric retention drug-loaded magnetic microbullet and its preparation method and application. It relates to the field of biomedicine technology. It comprises a microbullet shell, a magnet block and a drug. Under the guidance of an external magnetic field, the present invention can achieve positioning and long-term retention in the stomach, while slowly and continuously releasing drugs in the stomach to treat gastric diseases, avoiding the problem that gastric diseases are difficult to cure due to low drug concentration in the lesion site. By adjusting the number and aperture of the small holes at the bottom of the microbullet shell, the drug release rate can be adjusted, and personalized design can be made according to the needs of different diseases, and the retention time of the drug-loaded magnetic microbullet in the stomach can be controlled. After the drug-loaded magnetic microbullet has released the drug, the external magnet block is removed, and the drug-loaded magnetic microbullet is discharged from the body through the peristalsis of the gastrointestinal tract.

The invention provides application of a genetic regulation molecular axis in gastric lesion evolution discrimination and drug screening, and belongs to the technical field of biological medicines. The specific dynamic expression track of the lnc517368 / miR-203b-3p / SMAD2 axis in gastric lesion evolution is disclosed and defined for the first time, and brand new molecular basis and objective standard are provided for stage discrimination of gastric diseases. Meanwhile, an intervention strategy taking the axis as a target is defined, and a reliable screening and evaluation system is established for developing drugs for blocking or reversing the progress of stomach lesion. And by taking a turbid-dissolving and detoxifying formula as an example, reversible intervention of a disease evolution trajectory can be realized by adjusting the shaft, so that the method not only has important scientific theoretical value, but also shows wide conversion and application prospects in the aspects of disease diagnosis, drug research and development, clinical treatment strategy formulation and the like.